Thursday, March 30, 2023 6:25:28 PM
From my original email posted here in which i voiced my disappointment with Revive management...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171514727
His reply was that i should speak to and argue with the FDA because they're the governing body. He gave examples of other companies that had difficulties trying to get through to the FDA. And, shareholders knew the risks.
I responded with "A poorly designed clinical trial is not the FDA’s fault, the fault falls on Revive’s management."
In reply MF stated that the trial was designed with hospitalization and the environment changed.
In response i stated that for shareholder's sake i hope Revive has a good plan for moving forward.
His reply was for me to read the Press Releases.
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM